Skip to main content

Table 1 Baseline demographic and comorbidity characteristics by medication status of new bisphosphonate users at the end of 12 months follow up

From: Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries

Medication status of new bisphosphonate users at the end of 12 months follow up

 

Continued original bisphosphonate use

Discontinued without switching or restarting

Restarted the same bisphosphonates after a treatment gap

Switched to another anti-osteoporosis medication

N

9,510

7,827

1,819

2,296

Age, years (SD)

78 (6.8)

78 (6.8)

78 (6.7)

78 (6.8)

Median Household Income, $ (SD)

46,318 (22,808)

44,415 (22,715)

45,015 (23,123)

45,142 (22,540)

Sex

    

Female

8,562 (90.3)

6,965 (89.0)

1,639 (90.1)

2,104 (91.6)

Male

948 (10.0)

862 (11.0)

180 (9.9)

192 (8.4)

Race/ethnicity

    

Black

455 (4.8)

455 (5.8)

125 (6.9)

94 (4.1)

White

8,194 (86.2)

6,486 (82.9)

1,456 (80.0)*

1,920 (83.6)

Asian

360 (3.8)

319 (4.1)

92 (5.1)

130 (5.7)

Hispanic

285 (3.0)

382 (4.9)

95 (5.2)

107 (4.7)

Other

216 (2.3)

185 (2.4)

51 (2.8)

45 (2.0)

Geographic region

    

Northeast

1,717 (18.1)

1,340 (17.1)

355 (19.5)

382 (16.6)

Midwest

2,534 (26.6)

1,805 (23.1)

417 (22.9)

568 (24.7)

South

3,540 (37.2)

3,287 (42.0)

701 (38.5)

903 (39.3)

West

1,719 (18.1)

1,395 (17.8)

346 (19.0)

443 (19.3)

Charlson score

    

0

3,945 (41.5)

3,007 (38.4)

712 (39.1)

937 (40.8)

1-3

3,831 (40.3)

3,222 (42.2)

783 (43.0)

931 (40.5)

> 3

1,734 (18.2)

1,598 (20.4)

324 (17.8)

428 (18.6)

Hospitalizations

2,350 (24,7)

1,961 (25.1)

448 (24.6)

623 (27.1)*

In long-term care

1,146 (12.1)*

659 (8.4)

156 (8.6)

303 (13.2)

History of any fractures

1,051 (11.1)

704 (9.0)

162 (8.9)

272 (11.8)

History of DXA

5,641 (59.3)*

4,154 (53.1)

883 (48.5)

1,328 (57.8)

Dual Eligible

2,807 (29.5)

2,624 (33.5)

650 (35.7)

779 (33.9)

Eligible for low income subsidy

3,011 (31.7)

2,877 (36.8)

690 (37.9)

841 (36.6)

Entered Medicare part D coverage gap

1,826 (19.2)

1,613 (20.6)

367 (20.2)

471 (20.5)

Proton pump inhibitors

2,430 (25.6)

2,070 (26.5)

517 (28.4)

709 (30.9)

Doctor visit type

    

Internal Medicine visits

6,220 (65.4)

5,085 (65.0)

1,170 (64.3)

1,564 (68.1)

Family Practice visits

4,446 (46.8)

3,654 (46.7)

781 (42.9)

1,107 (48.2)

Medical Oncology visits

940 (9.9)

721 (9.2)

159 (8.7)

222 (9.7)

Rheumatology/Endo visits

1,706 (17.9)

1,150 (14.7)

304 (16.7)

430 (18.7)*

Number of Physician Visits

    

0-5

2,978 (31.3)

2,305 (29.4)

571 (31.4)

579 (25.2)

6-10

2,516 (26.5)

2,018 (25.8)

462 (25.4)

578 (25.2)

11-15

1,665 (17.5)

1,379 (17.6)

307 (16.9)

438 (19.1)

> 15

2,351 (24.7)

2,125 (27.1)

479 (26.3)

701 (30.5)

  1. Numbers in table are n (column percent) or mean (standard deviation).
  2. *Standardized difference score between current column and continued original bisphosphonate use column is greater than 0.1.